Very Interesting to read..
June ASCO Abstract
This is HUGE !!!!
Quote:"...Sipuleucel-T (Provenge) is effective when given either before or after androgen deprivation therapy (ADT) ..."
Quote:"...In 2013, after 2 to 4 weeks of follow-up, investigators concluded that sipuleucel-T was most helpful when administered after ADT. Now, after at least 6 months of follow-up, Antonarakis said, evidence seems to be pointing to sipuleucel-T before ADT as the strategy of choice..."
Quote:"...We need to have information about metastasis-free survival before we can determine whether these immune responses that we think might mean something actually mean something. In the next 6 to 12 months, we’ll present mature data on PSA [prostate-specific antigen] progression and metastasis-free survival in these patients, none of whom had evidence of metastatic disease when they enrolled....
The STAND study was the first to look at the combination of sipuleucel-T and ADT in patients with no metastases; the patients all were hormone therapy-naive, Antonarakis said."
This study will become the basis to change label to use Provenge as 1st line treatment, before ADT and before metastases !
Sentiment: Strong Buy
Go for it, spud.
Sentiment: Strong Sell
jail is not a laughing matter, and i am telling NOW!.............i am tired..............
i give you tomorrow to shoot this or ELSE!..........
August 15, 2014
Biotechnology organization Dendreon (DNDN) is not healthy in 2014. The organization has lost considerable value year-to-date and its first-quarter results didn't inspire any trust either, despite the fact that they were marginally better as compared to last year. Dendreon's tumor drug, Provenge, turned in feeble sales. As a result, despite cutting its losses from the year-back period, Dendreon shares declined.
On a year-over-year basis, the company observed an increase in its revenue without precedent for the quarter. Moreover, Dendreon says that sales of Provenge have stabilized despite confronting stiff competition from rivals. As a result, the organization expects that the drug's performance should enhance in the second quarter.
Better times ahead
Dendreon has stretched out beyond it given the solid development expected in the business sector for prostate growth drugs. As per Decision Resources, this business sector is relied upon to develop at a robust CAGR of 10% till 2022.
Dendreon has plans to make Provenge financially accessible in Europe, which will boost its growth. Anyhow before the marketing of any medication, safety is one of the paramount factors that influence drug acceptability. Dendreon had a successful meeting with the European Association of Urology, garnering a positive response from key sentiment leaders to incorporate Provenge in the new EAU prostate tumor guidelines.
Indeed, consensus findings suggest that European physicians are enthusiastic about Provenge.
The company has chalked out a two-step process for Provenge's European attempt. The first step includes
making the medication accessible to physicians and pa
View of NCT01981122 on 2014_08_22
ClinicalTrials Identifier: NCT01981122
Sipuleucel-T Helps ADT Boost Prostate Cancer Immunity - See more at: www.onclive.com/publications/urologists-in-cancer-care/2014/August-2014/Sipuleucel-T-Helps-ADT-Boost-Prostate-Cancer-Immunity#sthash.FUsP2Aap.dpuf